Caricamento...
Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study)
OBJECTIVE: Friedreich ataxia (FA) is a progressive genetic neurodegenerative disorder with no approved treatment. Omaveloxolone, an Nrf2 activator, improves mitochondrial function, restores redox balance, and reduces inflammation in models of FA. We investigated the safety and efficacy of omaveloxol...
Salvato in:
| Pubblicato in: | Ann Neurol |
|---|---|
| Autori principali: | , , , , , , , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley & Sons, Inc.
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7894504/ https://ncbi.nlm.nih.gov/pubmed/33068037 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ana.25934 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|